Abstract
The objective of this study was to determine the long-term efficacy of misoprostol in preventing diclofenac-induced gastroduodenal ulcers in rheumatoid arthritis and osteoarthritis patients. Three hundred eighty-four patients who had an endoscopically confirmed gastric or duodenal lesion that had healed with misoprostol therapy were randomized to receive misoprostol or placebo coadministered with diclofenac for up to 52 weeks. Endoscopic examinations were repeated at weeks 12, 24, and 52. The development of a gastric and/or duodenal ulcer was considered a prophylaxis failure. Results in the evaluable cohort of patients demonstrated that gastroduodenal ulcer incidences were lower with misoprostol than placebo for all study periods (0–12 weeks, 7% vs 23%; 0–24 weeks, 11% vs 26%; and 0–52 weeks, 15% vs 31%). Misoprostol did not interfere with the antiarthritic effects of diclofenac. In conclusion, misoprostol coadministered with diclofenac for 12 months to patients with rheumatoid arthritis or osteoarthritis significantly reduced the incidence of diclofenac-induced gastroduodenal ulcers (P≤0.018).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Baum C, Kennedy DL, Forbes MB: Utilization of nonsteroidal anti-inflammatory drugs. Arthritis Rheum 28(6):686–692, 1985
IMS (Intercontinental Medical Statistics) Publications: Pharmaceutical Database Division: 1990. IMS America Ltd., Plymouth Meeting, Pennsylvania; and IMS Medical World Review: UK and IMS America, 1989
Larkai EN, Smith JL, Lidsky MD, Graham DY: Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 82:1153–1158, 1987
Roth SH, Bennett RE: Nonsteroidal anti-inflammatory drug gastropathy. Arch Intern Med 147:2093–2100, 1987
Todd PA, Sorkin EM: Diclofenac sodium: A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 35:244–285, 1988
Geigy Pharmaceuticals: Voltaren (diclofenac sodium) prescribing information. September 1991
Griffin MR, Ray WA, Schaffner W: Nonsteroidal antiinflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med 109:359–363, 1988
Geis GS, Stead H, Wallemark C-B, Nicholson PA: Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAID in patients with rheumatoid arthritis or osteoarthritis, and interim report on prevention by misoprostol of diclofenac associated lesions. J Rheumatol 18(suppl 28):11–14, 1991
Steiner JA: Misoprostol clinical pharmacology: Establishment of activity in man. Dig Dis Sci 30:136S-141S, 1985
Dajani EZ, Nissen CH: Gastrointestinal cytoprotective effects of misoprostol: Clinical efficacy overview. Dig Dis Sci 30:194S-200S, 1985
Wilson DE: Antisecretory and mucosal protective actions of misoprostol. Am J Med 83(suppl 1A):2–8, 1987
Agrawal NM, Godiwala T, Arimura A, Dajani EZ: Cytoprotection by a synthetic prostaglandin against ethanol-induced gastric mucosal damage: A double-blind endoscopic study in human subjects. Gastrointest Endosc 32(2):67–70, 1986
Lanza F, Peace K, Gustitus L, Rack MF, Dickson B: A blinded endoscopic comparative study of misoprostol versus sucralfate and placebo in the prevention of aspirin-induced gastric and duodenal ulceration. Am J Gastroenterol 83:143–146, 1988
Lanza FL: A double-blind study of prophylactic effect of misoprostol on lesions of the gastric and duodenal mucosa induced by oral administration of tolmetin in healthy subjects. Dig Dis Sci 31:131S-136S, 1986
Aadland E, Fausa O, Vatn M, Cohen H, Quinlan D: Protection by misoprostol against naproxen-induced gastric mucosal damage. Am J Med 83(suppl 1A):37–40, 1987
Roth S, Agrawal N, Mahowald M, Montoya H, Robbins D, Miller S, Nutting E, Woods E, Crager M, Nissen C, Swabb E: Misoprostol heals gastroduodenal injury in patients with rheumatoid arthritis receiving aspirin. Arch Intern Med 149:775–779, 1989
Graham DY, Agrawal NM, Roth SH: Prevention of NSAID-induced gastric ulcer with misoprostol: Multicentre, double-blind, placebo-controlled trial. Lancet 3:1277–1280, 1988
Agrawal NM, Roth S, Graham DY, White RH, Germain B, Brown JA, Stromatt SC: Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. Ann Intern Med 115:195–200, 1991
Kaplan EL, Meier P: Nonparametric estimation from incomplete observation. J Am Stat Soc 53:457–481, 1958
Peto R, Peto J: Asymptotically efficient rank invariant procedures. J R Stat Soc 135 (series A):185–207, 1972
Fleiss JL: Statistical Methods for Rates and Proportions, 2nd ed. New York, John Wiley & Sons, 1981
Skoutakis VA, Carter CA, Mickle TR, Smith VH, Arkin CR, Alissandratos J, Petty DE: Review of diclofenac and evaluation of its place in therapy as a nonsteroidal antiinflammatory agent. Drug Intell Clin Pharm 22:850–859, 1988
Willkens RF: Worldwide clinical safety experience with diclofenac. Semin Arthritis Rheum 15(suppl 1):105–110, 1985
Catalano MA: Worldwide safety experience with diclofenac. Am J Med 80(suppl 4B):81–87, 1986
O'Brien WM: Adverse reactions to nonsteroidal antiinflammatory drugs. Am J Med 90(suppl 4B):70–80, 1986
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Agrawal, N.M., van Kerckhove, H.E.J.M., Erhardt, L.J. et al. Misoprostol coadministered with diclofenac for prevention of gastroduodenal ulcers. Digest Dis Sci 40, 1125–1131 (1995). https://doi.org/10.1007/BF02064210
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02064210